Skip to content
2000
Volume 21, Issue 6
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Introduction

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and angiotensin receptor neprilysin inhibitors (ARNi) are new classes of medications with an evolving role in heart failure (HF) patients. However, the effect of combining these drugs with cardiac resynchronization therapy (CRT) remains less certain.

Objective

This study aimed to investigate the impact of combined treatment with ARNi and SGLT2i on clinical and echocardiographic outcomes in CRT patients during 12-month follow-up.

Methods

HF patients with CRT implantation indications were enrolled in the non-randomized and retrospective study and were grouped in no ARNi and SGLT2i (1st group) and combined treatment with ARNi and SGLT2i (2nd group) cohorts. The CRT response criteria were as follows: improvement of NYHA class ≥1 and left ventricular end-systolic volume reduction ≥15% or left ventricular ejection fraction improvement ≥5% from the baseline during the 12-month follow-up.

Results

A total of 52 patients were included. At the 12-month follow-up, 18 of 35 (51.4%) patients in the 1st group and 16 of 17 patients (94.1%) in the 2nd cohort met CRT responder criteria (0.002). In multivariable logistic regression, combined treatment with ARNi and SGLT2i [odds ratio (OR): 20.09; 95% confidence interval (CI): 2.10-192.15; 0.009] and non-ischemic HF (OR 5.51; 95% CI 1.21-24.91; 0.026) were associated with CRT response.

Conclusion

The combined treatment with SGLT2i and ARNi in patients with CRT improved the echocardiographic and clinical outcomes during the 12-month follow-up. In our study cohort, the CRT response was associated with non-ischemic HF and combined treatment with ARNi and SGLT2i.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X350660250203111206
2025-03-14
2025-10-12

  • From This Site

    /content/journals/ccr/10.2174/011573403X350660250203111206
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ViraniS.S. AlonsoA. AparicioH.J. Heart disease and stroke statistics-2021 update: A report from the American Heart Association.Circulation20211438e254e74310.1161/CIR.0000000000000950 33501848
     [Google Scholar]
  2. BragazziN.L. ZhongW. ShuJ. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017.Eur. J. Prev. Cardiol.202128151682169010.1093/eurjpc/zwaa147 33571994
     [Google Scholar]
  3. AbumayyalehM. PilsingerC. El-BattrawyI. Clinical outcomes in patients with ischemic versus non-ischemic cardiomyopathy after angiotensin-neprilysin inhibition therapy.J. Clin. Med.20211021498910.3390/jcm10214989 34768510
     [Google Scholar]
  4. PaoliniC. MugnaiG. Dalla ValleC. Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up.Int. J. Cardiol. Heart Vasc.20213510082110.1016/j.ijcha.2021.100821 34179333
     [Google Scholar]
  5. McMurrayJ.J.V. SolomonS.D. InzucchiS.E. Dapagliflozin in patients with heart failure and reduced ejection fraction.N. Engl. J. Med.2019381211995200810.1056/NEJMoa1911303 31535829
     [Google Scholar]
  6. KimH.M. HwangI.C. ChoiW. YoonY.E. ChoG.Y. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.Sci. Rep.20211112234210.1038/s41598‑021‑01759‑5 34785723
     [Google Scholar]
  7. McDonaghT.A. MetraM. AdamoM. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.Eur. Heart J.202142363599372610.1093/eurheartj/ehab368 34447992
     [Google Scholar]
  8. GliksonM. NielsenJ.C. KronborgM.B. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy.Europace20222417116410.1093/europace/euab232 34455427
     [Google Scholar]
  9. SieniewiczB.J. GouldJ. PorterB. Understanding non-response to cardiac resynchronisation therapy: Common problems and potential solutions.Heart Fail. Rev.2019241415410.1007/s10741‑018‑9734‑8 30143910
     [Google Scholar]
  10. LeeM.M.Y. BrooksbankK.J.M. WetherallK. Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF).Circulation2021143651652510.1161/CIRCULATIONAHA.120.052186 33186500
     [Google Scholar]
  11. Santos-GallegoC.G. Vargas-DelgadoA.P. Requena-IbanezJ.A. Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction.J. Am. Coll. Cardiol.202177324325510.1016/j.jacc.2020.11.008 33197559
     [Google Scholar]
  12. DochertyK.F. JhundP.S. AnandI. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction: A prespecified analysis of DAPA-HF.Circulation2020142171623163210.1161/CIRCULATIONAHA.120.047480 32883108
     [Google Scholar]
  13. FondericoC. PergolaV. FaccendaD. Impact of sacubitril/valsartan and gliflozins on cardiac resynchronization therapy response in ischemic and non-ischemic heart failure patients.Int. J. Cardiol.202339313139110.1016/j.ijcard.2023.131391 37748521
     [Google Scholar]
  14. FondericoC PergolaV FaccendaD The role of sacubitril/ valsartan and gliflozins in heart failure with reduced ejection fraction after cardiac resynchronization therapy. medRxic20231710.1101/2023.03.30.23287985
     [Google Scholar]
  15. PitzalisM.V. IacovielloM. RomitoR. Ventricular asynchrony predicts a better outcome in patients with chronic heart failure receiving cardiac resynchronization therapy.J. Am. Coll. Cardiol.2005451656910.1016/j.jacc.2004.09.058 15629375
     [Google Scholar]
  16. PiresL.A. AbrahamW.T. YoungJ.B. JohnsonK.M. Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: Results from the multicenter insync randomized clinical evaluation (MIRACLE) and multicenter insync ICD randomized clinical evaluation (MIRACLE-ICD) trials.Am. Heart J.2006151483784310.1016/j.ahj.2005.06.024 16569543
     [Google Scholar]
  17. StraussD.G. SelvesterR.H. WagnerG.S. Defining left bundle branch block in the era of cardiac resynchronization therapy.Am. J. Cardiol.2011107692793410.1016/j.amjcard.2010.11.010 21376930
     [Google Scholar]
  18. BogossianH. LinzD. HeijmanJ. QTc evaluation in patients with bundle branch block.Int. J. Cardiol. Heart Vasc.20203010063610.1016/j.ijcha.2020.100636 32995475
     [Google Scholar]
  19. DouglasP.S. CarabelloB.A. LangR.M. 2019 ACC/AHA/ASE key data elements and definitions for transthoracic echocardiography: A report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards) and the American Society of Echocardiography.J. Am. Coll. Cardiol.201974340346910.1016/j.jacc.2019.02.027 31248701
     [Google Scholar]
  20. StilesM.K. FauchierL. MorilloC.A. WilkoffB.L. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing.Heart Rhythm2020171e220e22810.1016/j.hrthm.2019.02.034 31103461
     [Google Scholar]
  21. VaillantC. MartinsR.P. DonalE. Resolution of left bundle branch block-induced cardiomyopathy by cardiac resynchronization therapy.J. Am. Coll. Cardiol.201361101089109510.1016/j.jacc.2012.10.053 23352778
     [Google Scholar]
  22. AbrahamW.T. HayesD.L. Cardiac resynchronization therapy for heart failure.Circulation2003108212596260310.1161/01.CIR.0000096580.26969.9A 14638522
     [Google Scholar]
  23. ChatterjeeN.A. SinghJ.P. Cardiac resynchronization therapy: Past, present, and future.Heart Fail. Clin.201511228730310.1016/j.hfc.2014.12.007 25834976
     [Google Scholar]
  24. SharmaA. VermaS. BhattD.L. Optimizing foundational therapies in patients with HFrEF: How do we translate these findings into clinical care?JACC Basic Transl. Sci.20227550451710.1016/j.jacbts.2021.10.018 35663626
     [Google Scholar]
  25. McMurrayJ.J.V. AdamopoulosS. AnkerS.D. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC.Eur. Heart J.201233141787184710.1093/eurheartj/ehs104 22611136
     [Google Scholar]
  26. BurnettH. EarleyA. VoorsA.A. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: A network meta-analysis.Circ. Heart Fail.201710100352910.1161/CIRCHEARTFAILURE.116.003529 28087688
     [Google Scholar]
  27. McMurrayJ.J.V. PackerM. DesaiA.S. Angiotensin-neprilysin inhibition versus enalapril in heart failure.N. Engl. J. Med.201437111993100410.1056/NEJMoa1409077 25176015
     [Google Scholar]
  28. DesaiR.J. PatornoE. VaduganathanM. Effectiveness of angiotensin-neprilysin inhibitor treatment versus renin-angiotensin system blockade in older adults with heart failure in clinical care.Heart2021107171407141610.1136/heartjnl‑2021‑319405 34088766
     [Google Scholar]
  29. JanuzziJ.L. PrescottM.F. ButlerJ. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction.JAMA2019322111085109510.1001/jama.2019.12821 31475295
     [Google Scholar]
  30. KangD.H. ParkS.J. ShinS.H. Angiotensin receptor neprilysin inhibitor for functional mitral regurgitation.Circulation2019139111354136510.1161/CIRCULATIONAHA.118.037077 30586756
     [Google Scholar]
  31. KhanM.S. FelkerG.M. PiñaI.L. Reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with and without diabetes.JACC Heart Fail.20219213714510.1016/j.jchf.2020.09.014 33309581
     [Google Scholar]
  32. KobalavaZ. KotovskayaY. AverkovO. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction.Cardiovasc. Ther.201634419119810.1111/1755‑5922.12183 26990595
     [Google Scholar]
  33. PackerM. AnkerS.D. ButlerJ. Cardiovascular and renal outcomes with empagliflozin in heart failure.N. Engl. J. Med.2020383151413142410.1056/NEJMoa2022190 32865377
     [Google Scholar]
  34. YuristaS.R. SilljéH.H.W. Oberdorf-MaassS.U. Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction.Eur. J. Heart Fail.201921786287310.1002/ejhf.1473 31033127
     [Google Scholar]
  35. LopaschukG.D. VermaS. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review.JACC Basic Transl. Sci.20205663264410.1016/j.jacbts.2020.02.004 32613148
     [Google Scholar]
  36. DochertyK.F. JhundP.S. InzucchiS.E. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy.Eur. Heart J.202041252379239210.1093/eurheartj/ehaa183 32221582
     [Google Scholar]
  37. ZannadF. FerreiraJ.P. PocockS.J. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: A meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.Lancet20203961025481982910.1016/S0140‑6736(20)31824‑9 32877652
     [Google Scholar]
  38. YpenburgC. van BommelR.J. BorleffsC.J.W. Long-term prognosis after cardiac resynchronization therapy is related to the extent of left ventricular reverse remodeling at midterm follow-up.J. Am. Coll. Cardiol.200953648349010.1016/j.jacc.2008.10.032 19195605
     [Google Scholar]
  39. VerhaertD. GrimmR.A. PuntawangkoonC. Long-term reverse remodeling with cardiac resynchronization therapy: Results of extended echocardiographic follow-up.J. Am. Coll. Cardiol.201055171788179510.1016/j.jacc.2010.01.022 20413027
     [Google Scholar]
  40. MartensP. NijstP. VerbruggeF.H. DupontM. TangW.H.W. MullensW. Profound differences in prognostic impact of left ventricular reverse remodeling after cardiac resynchronization therapy relate to heart failure etiology.Heart Rhythm201815113013610.1016/j.hrthm.2017.08.021 28843420
     [Google Scholar]
  41. RizzelloV. PoldermansD. BoersmaE. Opposite patterns of left ventricular remodeling after coronary revascularization in patients with ischemic cardiomyopathy: Role of myocardial viability.Circulation2004110162383238810.1161/01.CIR.0000145115.29952.14 15477413
     [Google Scholar]
  42. SaidF. ter MaatenJ.M. MartensP. Aetiology of heart failure, rather than sex, determines reverse LV remodeling response to CRT.J. Clin. Med.20211023551310.3390/jcm10235513 34884215
     [Google Scholar]
  43. BlairH.A. Dapagliflozin: A review in symptomatic heart failure with reduced ejection fraction.Am. J. Cardiovasc. Drugs202121670171010.1007/s40256‑021‑00503‑8 34651263
     [Google Scholar]
  44. AnkerS.D. ButlerJ. FilippatosG. Empagliflozin in heart failure with a preserved ejection fraction.N. Engl. J. Med.2021385161451146110.1056/NEJMoa2107038 34449189
     [Google Scholar]
  45. CurtainJ.P. DochertyK.F. JhundP.S. Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF.Eur. Heart J.202142363727373810.1093/eurheartj/ehab560 34448003
     [Google Scholar]
  46. SfairopoulosD. ZhangN. WangY. Association between sodium–glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: A meta-analysis of randomized controlled trials.Europace2022241203010.1093/europace/euab177 34333592
     [Google Scholar]
  47. YancyC.W. JessupM. BozkurtB. 2013 ACCF/AHA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation2013128161810185210.1161/CIR.0b013e31829e8807 23741057
     [Google Scholar]
  48. AhmadT. DesaiN. WilsonF. Clinical implications of cluster analysis-based classification of acute decompensated heart failure and correlation with bedside hemodynamic profiles.PLoS One2016112014588110.1371/journal.pone.0145881 26840410
     [Google Scholar]
  49. ForresterJ.S. DiamondG. ChatterjeeK. SwanH.J.C. Medical therapy of acute myocardial infarction by application of hemodynamic subsets (first of two parts).N. Engl. J. Med.1976295241356136210.1056/NEJM197612092952406 790191
     [Google Scholar]
  50. ZhouX. ZhuH. ZhengY. TanX. TongX. A systematic review and meta-analysis of sacubitril-valsartan in the treatment of ventricular remodeling in patients with heart failure after acute myocardial infarction.Front. Cardiovasc. Med.2022995394810.3389/fcvm.2022.953948 36304540
     [Google Scholar]
  51. CarvalhoP.E.P. VeigaT.M.A. Simões e SilvaA.C. Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: A meta-analysis of randomized controlled trials.Clin. Res. Cardiol.202311281044105510.1007/s00392‑022‑02148‑2 36592186
     [Google Scholar]
  52. MorrowD.A. VelazquezE.J. DesaiA.S. Sacubitril/valsartan in patients hospitalized with decompensated heart failure.J. Am. Coll. Cardiol.202483121123113210.1016/j.jacc.2024.01.027
     [Google Scholar]
  53. ChenD.Y. ChenC.C. TsengC.N. Clinical outcomes of Sacubitril/Valsartan in patients with acute heart failure: A multi-institution study.EClin Med20214110114910.1016/j.eclinm.2021.101149
     [Google Scholar]
  54. SonaglioniA. LonatiC. TescaroL. Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older.Aging Clin. Exp. Res.20223451081109410.1007/s40520‑021‑02025‑4 34988931
     [Google Scholar]
  55. MazzaA. TownsendD.M. TorinG. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.Biomed. Pharmacother.202013011059610.1016/j.biopha.2020.110596 34321170
     [Google Scholar]
  56. AmiokaM. KinoshitaH. FujiY. Long-term efficacy of SGLT2 inhibitors for elderly patients with acute decompensated heart failure: The OASIS-HF study.ESC Heart Fail.202412144745510.1002/ehf2.15088 39340221
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X350660250203111206
Loading
Impact of Combined Treatment with ARNi and SGLT2i on Clinical and Echocardiographic Outcomes in Patients with CRT During Mid-term Period
Curr. Cardiol. Rev. 21, e1573403X350660 (2025); https://doi.org/10.2174/011573403X350660250203111206
/content/journals/ccr/10.2174/011573403X350660250203111206
/content/journals/ccr/10.2174/011573403X350660250203111206
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): angiotensin receptor neprilysin inhibitors; cardiac resynchronization therapy; clinical outcomes; echocardiographic outcomes; Heart failure; sodium-glucose co-transporter 2 inhibitors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test